Short report of potential Myelinogenesis effects of taper up-off of opium tincture in rodent model of multiple sclerosis

Multiple sclerosis (MS) is one of the most common demyelinating autoimmune diseases that affects the central nervous system and is characterized by major immune-mediated myelin and axonal damage or axonal loss explicable to the absence of myelin sheaths. Here we present the early findings of the gene expression study of meylinogenesis-related genes of MS rat models which were treated with a novel protocol of taper up-off of opium tincture. The study included normal Lewis rats, MS rat models by induction of experimental autoimmune encephalomyelitis (EAE) without treatment, and MS rat models with a novel protocol of taper up-off treatment of opium tincture called Dezhakam-step-time (DST) in different dosages. RNA was extracted and cDNA was synthesized from the spinal cord tissue. Gene expression analysis was conducted for eight genes as markers of myelinogenesis ( OLIG1 , OLIG2 , MBP , MYRF , PLP1 , PMP22 , EGF , and UGT8 ) using the Real time PCR. All eight genes were down-regulated in EAE models vs. healthy controls and all eight genes were up-regulated after the taper up-off treatment of opium tincture. The most over-expression of myelinogenesis-related genes was revealed at higher dosages of opium tincture. These are the early results of a gene expression study in a multiple sclerosis model treated with opium tincture. It seems that the opium tincture method may induce the activation of myelinogenesis in EAE models which could lead to a potential treatment for improvement of neural dysfunctions in MS patients.